After ejecting out of Bristol Myers R&D, Rupert Vessey lands at the top science post at a buzzy Flagship
Five months ago, Rupert Vessey stepped out of his influential R&D post at Bristol Myers Squibb in a move clearly pointing to a new, though unannounced, chapter in biotech. And he unveiled his next career step today with the news that he’s joining a buzzy Flagship Pioneering as their chief scientist.
It’s a brand new position.
The move takes him out of a Big Pharma that’s been working, sometimes struggling, to manage a major pipeline — including a host of drugs Vessey arranged to in-license for big bucks — and puts him squarely at one of the largest venture groups in biotech, where he’ll be widely familiar to the people mustering new companies around some emerging technologies.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.
